# A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus

> **NCT01028963** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 159 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Placebo
- **DRUG:** pioglitazone
- **DRUG:** CCX140-B
- **DRUG:** CCX140-B

## Key facts

- **NCT ID:** NCT01028963
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-10
- **Final completion:** 2010-11
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01028963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01028963, "A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01028963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*